Chugai Pharmaceutical Co.

New Capabilities

Developed Enspryng using its proprietary antibody recycling technology

The FDA approved Roche's Enspryng for thyroid eye disease on October 15, the first and only at-home subcutaneous treatment for the condition. Patients or caregivers inject the drug with a prefilled syringe or pen after a healthcare provider's training, with no infusion clinic visits.

Updated Oct 17